Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

  • New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed Mayzent treatment1
     
  • Separate post-hoc analysis from EXPAND demonstrated Mayzent reduced cortical grey matter (cGM) and thalamic atrophy in patients with SPMS2, outcomes associated with long-term irreversible disability accumulation3
     
  • Mayzent is the first and only oral disease modifying …
/by

Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

  • New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed Mayzent treatment1
     
  • Separate post-hoc analysis from EXPAND demonstrated Mayzent reduced cortical grey matter (cGM) and thalamic atrophy in patients with SPMS2, outcomes associated with long-term irreversible disability accumulation3
     
  • Mayzent is the first and only oral disease modifying …
/by